Division of Endocrinology, Diabetes and Metabolism, John H Stroger Jr Hospital of Cook County, Chicago; Department of Endocrinology, Diabetes and Metabolism, Rush University Hospital, Chicago, IL, USA.
Diabetes Metab Syndr Obes. 2012;5:1-10. doi: 10.2147/DMSO.S15404. Epub 2012 Jan 10.
We have now at our disposal the new rapid-acting insulin analogs, of which insulin lispro was the first to become commercially available. While the differences in pharmacokinetic and pharmacodynamic characteristics are indisputable, the clinical benefits attained by these changes have not been as clear. In the present review, we discuss the structure, pharmacology, and landmark studies related to insulin lispro. The clinical characteristics of insulin lispro are compared with those of insulin regular and other insulin analogs in different clinical situations. Also included are the aspects of quality of life and cost-effectiveness that may modify the modern practitioner's decision to adopt one type of insulin over another.
我们现在可以使用新的速效胰岛素类似物，其中胰岛素赖脯氨酸是第一个上市的。虽然药代动力学和药效学特征的差异是无可争议的，但这些变化所带来的临床益处并不明显。在本综述中，我们讨论了胰岛素赖脯氨酸的结构、药理学和相关的标志性研究。将胰岛素赖脯氨酸的临床特征与不同临床情况下的常规胰岛素和其他胰岛素类似物进行了比较。还包括可能改变现代从业者选择使用一种胰岛素而不是另一种胰岛素的生活质量和成本效益方面。
